Repurposing β-Lactams for the Treatment of Mycobacterium kansasii Infections: An In Vitro Study.
Ontology highlight
ABSTRACT: Mycobacterium kansasii (Mkn) causes tuberculosis-like lung infection in both immunocompetent and immunocompromised patients. Current standard therapy against Mkn infection is lengthy and difficult to adhere to. Although β-lactams are the most important class of antibiotics, representing 65% of the global antibiotic market, they have been traditionally dismissed for the treatment of mycobacterial infections, as they were considered inactive against mycobacteria. A renewed interest in β-lactams as antimycobacterial agents has shown their activity against several mycobacterial species, including M. tuberculosis, M. ulcerans or M. abscessus; however, information against Mkn is lacking. In this study, we determined the in vitro activity of severa
SUBMITTER: Munoz-Munoz L
PROVIDER: S-EPMC9952313 | biostudies-literature | 2023 Feb
REPOSITORIES: biostudies-literature
ACCESS DATA